A multicenter study of precise treatment for children with acute promyelocytic leukemia

Children with Acute Promyelocytic Leukemia treated with CCLG-2016 regemin in multicenter

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-16009670

Enrollment

Unknown

Registered

2016-10-28

Start date

2016-11-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Promyelocytic Leukemia

Interventions

low risk group:treatment regimen for low risk group patients

high risk group:treatment regimen for high risk group patients

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The diagnosis of APL was confirmed based on FAB, t(15;17), FISH/RT-PCR for the PML-RARa fusion gene; 2. Children less than 18 years old; 3. Normal heart function; 4. Sign consent form.

Exclusion criteria

Exclusion criteria: 1. The relapsing patients used arsenic trioxide before; 2. allergic to arsenic trioxide; 3. Family members cannot understand the treatment regimen; 4. Contraindicated to anthracene-based chemotherapy; 5. Participate in other clinical researchers at the same time; 6.Other various situations that making the research hard to process.

Design outcomes

Primary

Measure	Time frame
overall survival;event-free survival;Hematological complete remission;Molecular complete remission;	—

Countries

China

Contacts

Public ContactJiang Hui

Children's Hospital of Shanghai

jhui0111@126.com+86 18917129021

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026